Jun. 3 at 9:51 PM
$BCRX Takhzyro total sales is around
$1.5B and patients have to inject every two week. Moreover it has citric acid which causes injection-site reaction —pain, redness, bruising, swelling, or itching where the drug is injected.
If Navanibert is approved with same efficacy and once every 3 or 6 month dosing with no local pain since it does not have citric acid, I think conservatively at least 1/3 patients will switch or 0.5B in revenue.
BCRX already know they will get to 1B revenue, they are now really shooting for
$2B
